Wei Ouyang

Wei Ouyang

Auto-generated profile, based on publicly available information

Wei Ouyang

Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
WOWei Ouyang
Wei Ouyang
MWMing-Da Wang
Ming-Da Wang
WWWan-Yin Wang
Wan-Yin Wang
CLChao Li
Chao Li
LYLan-Qing Yao
Lan-Qing Yao
TYTian Yang
Tian Yang
Hepatocellular carcinoma (HCC) is a highly lethal and heterogeneous malignancy with multiple genetic alternations and complex signaling pathways. The complexity and multifactorial nature of HCC pose a tremendous challenge regarding its diagnosis and treatment. Emerging evidence has indicated an important regulatory role of epigenetic modifications in HCC initiation and progression. Epigenetic modifications are stably heritable gene expression traits caused by changing the accessibility of chromatin structure and genetic activity without alteration in the DNA sequence and have been gradually recognized as a hallmark of cancer. In addition, accumulating data suggest a potential value of altered hydroxymethylation in epigenetic modifications and therapeutics targeting the epigenetically mediated regulation. As such, probing the epigenetic field in the era of precision oncology is a valid avenue for promoting the accuracy of early diagnosis and improving the oncological prognosis of HCC patients. This review focuses on the diagnostic performance and clinical utility of 5-hydroxymethylated cytosine, the primary intermediate product of the demethylation process, for early HCC diagnosis and discusses the promising applications of epigenetic-based therapeutic regimens for HCC.